Onconova Therapeutics Touts Additional Positive Data For Rigosertib Monotherapy In Skin Cancer Setting
Onconova Therapeutics Inc (NASDAQ:ONTX) announced that the second of two evaluable participants in the Phase 2 program of rigosertib…
Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) provided preliminary 2022 fourth quarter and full-year total revenues estimates, a forecast of 2023 total…
PacBio To Expand MAS-Seq Technology To 16S rRNA And Bulk RNA-Seq Solutions
End-to-End Solutions Planned to Support Key Customer Applications With Increased Cost Flexibility on Long-Read Sequencing Systems
MENLO PARK, Calif., Feb. 7, 2023 /PRNewswire/
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
Roche Holdings AG (OTC:RHHBY) has announced results from the global phase 3 COMMODORE 2 study, evaluating the efficacy and…
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site For INDP-D101 Phase 1 Open-Label Trial of Decoy20 In Patients With Advanced Solid Tumors
The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK),
AC Immune Awarded New Grants From MJFF, Target ALS Supporting Programs Targeting TDP-43
The Michael J. Fox Foundation grant supports the development of AC Immune's first-in-class TDP-43 PET tracer program
Target ALS Foundation grant supports collaboration between AC Immune and world-class
Teva Granted FDA Tentative Approval For Type 5 – New Formulation or New Manufacturer Of PACLITAXEL
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216338
T2 Biosystems Advances To The Phase 2 In HHS And The Steven And Alexandra Cohen Foundation’s LymeX Diagnostics Prize
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of
Axcella Health Will Be Issued U.S. Patent Number 11,571,404 Tomorrow Titled “Compositions And Methods For The Treatment Of Liver Diseases And Disorders Associated With One Or Both Of Hyperammonemia Or Muscle Wasting”
https://twitter.com/PatentGrants/status/1622660323923890177
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
Bristol-Myers Squibb & Co (NYSE:BMY) has returned the exclusive rights to Dragonfly Therapeutics‘ IL-12 oncology candidate. In 2020, BMS handed out $475 million in…